Transdermal physostigmine-absence of effect on topographic brain mapping.
Nine patients with primary degenerative dementia (PDD) participated in an open trial of transdermal physostigmine (TPh). In order to evaluate the neurophysiologic effects of TPh, EEG data were recorded and compared at baseline and following 2 months of continuous treatment. There was no significant effect of TPh on EEG spectra in patients with PDD.
Department of Neurology, Tel-Aviv Sourasky Medical Center and Sackler School of Medicine, Israel.
M Y
MY
Neufeld
Department of Neurology, Tel-Aviv Sourasky Medical Center and Sackler School of Medicine, Israel.
F
F
Mawassi
Israel Institute for Biological Research, Ness Ziona, Israel.
A
A
Levy
Department of Neurology, Tel-Aviv Sourasky Medical Center and Sackler School of Medicine, Israel.
T A
TA
Treves
Department of Neurology, Tel-Aviv Sourasky Medical Center and Sackler School of Medicine, Israel.
A D
AD
Korczyn
Alzheimer's disease; Brain mapping; Dementia; EEG; Physostigmine